Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

中和 抗体 病毒学 贪婪 表位 生物 重链 2019年冠状病毒病(COVID-19) 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 恢复期血浆 中和抗体 病毒 免疫学 医学 传染病(医学专业) 疾病 病理
作者
Jianliang Xu,Kai Xu,Seolkyoung Jung,A. Conte,Jenna Ariel Lieberman,Frauke Muecksch,Julio C. C. Lorenzi,Solji Park,Fabian Schmidt,Zijun Wang,Yaoxing Huang,Yang Luo,Manoj S. Nair,Pengfei Wang,Jonathan E. Schulz,Lino Tessarollo,Tatsiana Bylund,Gwo‐Yu Chuang,Adam S. Olia,Tyler Stephens,I‐Ting Teng,Yaroslav Tsybovsky,Tongqing Zhou,Vincent J. Munster,David D. Ho,Théodora Hatziioannou,Paul D. Bieniasz,Michel C. Nussenzweig,Peter D. Kwong,Rafael Casellas
出处
期刊:Nature [Nature Portfolio]
卷期号:595 (7866): 278-282 被引量:174
标识
DOI:10.1038/s41586-021-03676-z
摘要

Abstract Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide. Although a number of vaccines have been deployed, the continual evolution of the receptor-binding domain (RBD) of the virus has challenged their efficacy. In particular, the emerging variants B.1.1.7, B.1.351 and P.1 (first detected in the UK, South Africa and Brazil, respectively) have compromised the efficacy of sera from patients who have recovered from COVID-19 and immunotherapies that have received emergency use authorization 1–3 . One potential alternative to avert viral escape is the use of camelid VHHs (variable heavy chain domains of heavy chain antibody (also known as nanobodies)), which can recognize epitopes that are often inaccessible to conventional antibodies 4 . Here, we isolate anti-RBD nanobodies from llamas and from mice that we engineered to produce VHHs cloned from alpacas, dromedaries and Bactrian camels. We identified two groups of highly neutralizing nanobodies. Group 1 circumvents antigenic drift by recognizing an RBD region that is highly conserved in coronaviruses but rarely targeted by human antibodies. Group 2 is almost exclusively focused to the RBD–ACE2 interface and does not neutralize SARS-CoV-2 variants that carry E484K or N501Y substitutions. However, nanobodies in group 2 retain full neutralization activity against these variants when expressed as homotrimers, and—to our knowledge—rival the most potent antibodies against SARS-CoV-2 that have been produced to date. These findings suggest that multivalent nanobodies overcome SARS-CoV-2 mutations through two separate mechanisms: enhanced avidity for the ACE2-binding domain and recognition of conserved epitopes that are largely inaccessible to human antibodies. Therefore, although new SARS-CoV-2 mutants will continue to emerge, nanobodies represent promising tools to prevent COVID-19 mortality when vaccines are compromised.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
充电宝应助颠覆乾坤采纳,获得10
1秒前
2秒前
无花果应助pz采纳,获得10
2秒前
zheng完成签到 ,获得积分10
4秒前
量子星尘发布了新的文献求助10
5秒前
星辰大海应助荔枝采纳,获得10
5秒前
LJL发布了新的文献求助10
6秒前
meng发布了新的文献求助10
6秒前
无私的颤完成签到,获得积分10
6秒前
lucky完成签到 ,获得积分10
7秒前
Zel博博完成签到,获得积分10
7秒前
谷粱诗云完成签到,获得积分10
7秒前
yar应助myuniv采纳,获得10
7秒前
xc完成签到 ,获得积分10
8秒前
8秒前
干净的天与完成签到,获得积分10
8秒前
哈基米德应助毅诚菌采纳,获得10
10秒前
铁甲小杨完成签到,获得积分0
10秒前
11秒前
卡机了完成签到,获得积分10
12秒前
平淡绿柏完成签到,获得积分10
14秒前
架子猫发布了新的文献求助10
14秒前
14秒前
颠覆乾坤发布了新的文献求助10
15秒前
乔乔完成签到,获得积分10
16秒前
学术小白完成签到,获得积分10
16秒前
min完成签到,获得积分10
16秒前
16秒前
汉堡包应助slin_sjtu采纳,获得10
16秒前
czx完成签到,获得积分10
17秒前
szxnb666发布了新的文献求助30
17秒前
MRJJJJ完成签到,获得积分10
17秒前
chaser完成签到,获得积分10
17秒前
光亮白山完成签到 ,获得积分10
18秒前
科研通AI2S应助大橙子采纳,获得10
18秒前
18秒前
小马甲应助meng采纳,获得10
19秒前
pz发布了新的文献求助10
19秒前
zhou1216完成签到 ,获得积分10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022